Insider buying last 90 days
No open-market insider purchases were filed for PTGX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PTGX insider filing, plotted on the chart in Gekko.Open PTGX in Gekko
NASDAQ: PTGX
Protagonist Therapeutics (PTGX) Stock Analysis & Forecast
Sep 28 close
$142.44+0.58 (+0.4%)
Gekko Brief
AI summaryThis week's news centers on Protagonist Therapeutics' icotrokinra program, with Johnson & Johnson submitting an application to the European Medicines Agency for the oral peptide in moderate-to-severe plaque psoriasis. Analyst attention has also picked up, with Argus raising its target price to $152.00, while other coverage cites a "Moderate Buy" consensus and an average price target of $147.13. Separately, short interest was reported at 8.14 million shares, representing 13.27% of the public float.
PTGX closed at $142.44, up 0.4%, with the stock sitting between its 50-day average of $144.63 and its 200-day average of $110.30. Momentum over the past month is negative at -4.7%, though three-month and six-month returns stand at 17.1% and 43.9% respectively. The GekkoIndex reads 61.8, placing the stock in the Accumulation zone, and the current price sits 9.1% below the Gekko Fair Value of $156.64.
The next earnings date falls on 5 November 2026, 37 days out and beyond a typical 20-trading-day window; the prior quarter saw an EPS miss of -0.69 against a -0.34 estimate, with a 4.6% reaction. No insider, Congress, or unusual options activity appears in the recent windows, though one billionaire holder is recorded. Seasonally, the next 20 trading days have averaged a 17.4% return over 5 years, rising in 3 of them. Analyst sentiment remains uniformly positive, with all 12 tracked firms rating the stock a buy and a consensus target of $174.69.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Protagonist Therapeutics price vs fair value
Close $142.44200-day averageGekko Fair Value $156.64
Protagonist Therapeutics quick facts
- Market cap
- $9.16B
- P/E ratio
- 134.7
- Forward P/E
- 36.9
- EPS, TTM
- $1.02
- Revenue, TTM
- $282.0M
- Profit margin
- 29.4%
- Dividend yield
- —
- Beta
- 1.79
- Volume
- 925,456 avg 677,355
- 1-year return
- +120.2%
- Typical daily move
- ±3.6%
- Typical 20-day move
- ±10.7%
- 50-day average
- $144.63
- 200-day average
- $110.30
- Next earnings
- Nov 5
- Shares outstanding
- 64.71M
Protagonist Therapeutics swing-trade checklist
Protagonist Therapeutics scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $142.44 sits between the 50-day ($144.63) and 200-day ($110.30) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
61.8, Accumulation
Reading 61.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
9.1% below
Price is 9.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+17.4% on average
From this point in the calendar, the next 20 trading days averaged +17.4% over 5 years, rising in 3 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Protagonist Therapeutics stock chart and price history
Protagonist Therapeutics closed at $142.44 on Sep 28, 2026, +120.2% over the past year, inside a 52-week range of $62.24 to $160.81.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −4.7%
- 3 months
- +17.1%
- 6 months
- +43.9%
- 1 year
- +120.2%
The full PTGX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PTGX in Gekko
Follow Protagonist Therapeutics through every session
Put PTGX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PTGX in GekkoFree for 7 days. No credit card required.
About Protagonist Therapeutics
Protagonist Therapeutics develops therapies built around peptide molecules, with work concentrated on blood disorders and on conditions driven by inflammation or immune activity. It is best recognized for rusfertide, also called PTG-300, an injectable compound that mimics hepcidin and is being tested in Phase II studies for polycythemia vera, hereditary hemochromatosis, and related blood conditions. Alongside this, the company is developing PN-943, an oral peptide designed to block alpha-4-beta-7 integrin for inflammatory bowel disease, and PN-235, an oral compound aimed at the interleukin-23 receptor for both IBD and other conditions outside that category.
The company advances its pipeline in part through a licensing and collaborative arrangement with Janssen Biotech, Inc., pairing its own drug discovery work with an outside partner as programs move through development.
Protagonist Therapeutics was founded in 2006 and is headquartered in Newark, California. Its shares trade on the NASDAQ under the ticker PTGX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- protagonist-inc.com
Protagonist Therapeutics GekkoIndex: the smart money zone
Protagonist Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 61.8, in the Accumulation zone, up 0.7 points over five sessions.
61.8Accumulation
Up 0.7 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 7 | Too few readings yet | |||
| Accumulation (current zone) | 139 | +2.0% | +6.9% | ||
| Neutral | 482 | +1.6% | +6.5% | ||
| Distribution | 40 | −0.9% | +0.6% | ||
| Selling | 4 | Too few readings yet | |||
Average PTGX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the PTGX price, zone by zone.Track PTGX in Gekko
Is Protagonist Therapeutics stock overvalued? Gekko Fair Value
Protagonist Therapeutics trades 9.1% below Gekko Fair Value of $156.64, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Protagonist Therapeutics shares are worth, recalculated every trading day.
$156.64
Gekko Fair Value, Sep 26, 2026
9.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open PTGX in Gekko
Protagonist Therapeutics insider and Congress trading
No open-market insider purchases were filed for Protagonist Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PTGX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PTGX, plotted on the chart in Gekko.Open PTGX in Gekko
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds PTGX.
1added0opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko
Protagonist Therapeutics earnings: next date and track record
Protagonist Therapeutics reports on Nov 5, 2026 (37 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 5, 2026
37 days away
- EPS estimate
- $2.43
- Revenue estimate
- $240.1M
4 of 8reports beat the EPS estimate
±3.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Mar 18, 2026 | −$0.69 est −$0.34 | — | +4.6% |
| Nov 6, 2025 | −$0.62 est −$0.59 | $4.71M est $14.92M | +2.1% |
| Aug 6, 2025 | −$0.55 est −$0.53 | $5.55M est $8.43M | −5.5% |
| May 5, 2025 | −$0.19 est $0.11 | $28.32M est $6.56M | −7.7% |
| Feb 25, 2025 | $1.98 est $0.25 | — | +0.4% |
| Nov 4, 2024 | −$0.54 est −$0.60 | $4.68M est $38.81M | −1.8% |
| Aug 6, 2024 | −$0.50 est −$0.60 | $4.17M est $8.00M | 0.0% |
| May 7, 2024 | $3.26 est $1.19 | $255.0M est $120.0M | +4.0% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Protagonist Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Protagonist Therapeutics is $174.69, +22.6% from the last close, from 12 firms rating the stock in the last 90 days.
$174.69consensus 12-month target, +22.6% from the last close
Now $142.44Avg $174.69
Low $121High $186
Each firm’s latest rating in the last 90 days: 12 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 9 | Citi | $182 | +27.8% |
| Sep 1 | H.C. Wainwright | $170 | +19.3% |
| Sep 1 | Citi | $182 | +27.8% |
| Sep 1 | Truist Financial | — | — |
| Aug 31 | Wedbush | $173 | +21.5% |
+6.9%average 20-day move after past Accumulation readings
+17.4%average move over the next 20 trading days in the last 5 years
±3.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Protagonist Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Protagonist Therapeutics averaged +17.4% across the last 5 years, rising in 3 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.1% | 2 of 5 |
| Next 10 trading days | +19.5% | 4 of 5 |
| Next 15 trading days | +15.3% | 3 of 5 |
| Next 20 trading days | +17.4% | 3 of 5 |
| Next 30 trading days | +26.7% | 4 of 5 |
For scale, PTGX’s typical 20-trading-day move in either direction is about 10.7%.
Protagonist Therapeutics market cap and key statistics
Protagonist Therapeutics’s market cap is $9.16B, with a P/E ratio of 134.7 and revenue of $282.0M over the last twelve months.
Valuation
- Market cap
- $9.16B
- P/E ratio
- 134.7
- Forward P/E
- 36.9
- EPS, TTM
- $1.02
- Gekko Fair Value
- $156.64
Trading
- Volume
- 925,456
- Avg volume, 20 days
- 677,355
- 52-week high
- $160.81
- 52-week low
- $62.24
- Shares outstanding
- 64.71M
Financials
- Revenue, TTM
- $282.0M
- Profit margin
- 29.4%
- Return on equity
- 11%
- Quarterly earnings growth, YoY
- +351.3%
Risk and income
- Beta
- 1.79
- Typical daily move
- ±3.6%
- Typical 20-day move
- ±10.7%
Protagonist Therapeutics stock news this week
Coverage of Protagonist Therapeutics this week reads positive: 5 positive, 0 neutral and 1 negative headlines.
- Here's How Much $100 Invested In Protagonist Therapeutics 10 Years Ago Would Be Worth TodayBenzinga, Sep 28
- Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines AgencyMontgomery Advertiser, Sep 26
- Protagonist Therapeutics (NASDAQ:PTGX) Shares Gap Up - What's Next?MarketBeat, Sep 25
- Protagonist Therapeutics (PTGX) Short Interest & Short Float | Updated Sep 2026MarketBeat, Sep 25
- Protagonist Therapeutics, Inc. (PTGX) Stock forecastsYahoo Finance Singapore, Sep 24
- Protagonist Therapeutics (NASDAQ:PTGX) & MiMedx Group (NASDAQ:MDXG) Head-To-Head ReviewDefense World, Sep 24
Protagonist Therapeutics peers
Protagonist Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Protagonist Therapeutics stock FAQ
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $9.16B at the Sep 28, 2026 close of $142.44, with 64.71M shares outstanding. The shares trade on a P/E ratio of 134.7.
What is the Protagonist Therapeutics stock forecast?
The consensus analyst 12-month price target for Protagonist Therapeutics is $174.69, +22.6% from the last close. Of the 12 firms that rated the stock in the last 90 days, 12 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Protagonist Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Protagonist Therapeutics is undervalued: the Sep 28, 2026 close of $142.44 is 9.1% below Gekko Fair Value of $156.64. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Protagonist Therapeutics report earnings next?
Protagonist Therapeutics is expected to report on Nov 5, 2026 (37 days away). Analysts expect earnings of $2.43 per share on revenue of $240.1M. Protagonist Therapeutics beat the earnings estimate in 4 of its last 8 reports, moving 3.3% on average across the report.
What is Protagonist Therapeutics’s 52-week high and low?
Protagonist Therapeutics’s 52-week high is $160.81 and its 52-week low is $62.24; it closed at $142.44 on Sep 28, 2026, +120.2% over the past year.
Is Protagonist Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Protagonist Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.